Search results
Showing 601 to 615 of 1422 results for social care
Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management (CG84)
This guideline covers diagnosing, managing and referring infants and young children younger than 5 years who present with acute diarrhoea (lasting up to 14 days) with or without vomiting. It aims to improve the diagnosis and management of infective gastroenteritis and appropriate escalation of care.
This quality standard covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS208Show all sections
Sections for QS208
- Quality statements
- Quality statement 1: Structured education programmes
- Quality statement 2: Continuous glucose monitoring
- Quality statement 3: Statin therapy for primary prevention of cardiovascular disease
- Quality statement 4: 9 key care processes
- Quality statement 5: Assessing the risk of diabetic foot problems on admission to hospital
- Quality statement 6: Support to self-manage diabetes during inpatient admissions
- Quality statement 7 (placeholder): Identification of eating disorders in adults with type 1 diabetes
Obesity in children and young people: prevention and lifestyle weight management programmes (QS94)
This quality standard covers preventing children and young people (under 18) from becoming overweight or obese, including strategies to increase physical activity and promote a healthy diet in the local population. It also covers lifestyle weight management programmes for children and young people who are overweight or obese. It describes high-quality care in priority areas for improvement.
View quality statements for QS94Show all sections
Sections for QS94
- Quality statements
- Quality statement 1: Vending machines
- Quality statement 2: Nutritional information at the point of choosing food and drink options
- Quality statement 3: Prominent placement of healthy options
- Quality statement 4: Maintaining details of local lifestyle weight management programmes
- Quality statement 5: Raising awareness of lifestyle weight management programmes
- Quality statement 6: Family involvement in lifestyle weight management programmes
- Quality statement 7: Evaluating lifestyle weight management programmes
Patient Status Engine for wireless monitoring of vital signs (MIB271)
NICE has developed a medtech innovation briefing (MIB) on the Patient Status Engine for wireless monitoring of vital signs .
How to submit a new medical technology to NICE for guidance
This guideline covers assessing and managing pelvic fractures, open fractures and severe ankle fractures (known as pilon fractures and intra-articular distal tibia fractures) in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It aims to reduce deaths and long-term health problems by improving the quality of emergency and urgent care.
Vamorolone for treating Duchenne muscular dystrophy [ID4024]
In development [GID-TA11135] Expected publication date: TBC
COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)
The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection.
Show all sections
the UK Affiliate's approach to reimbursement across the UK. This involves care pathway analysis and value proposition development,...
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.
This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.
We want you to tell us what matters to you, your organisation or your community.
Our tool to help you plan for and implement NICE guidance. View upcoming guidance and understand the impact of guidance on your resources.
Spesolimab for treating generalised pustular psoriasis flares [ID3963]
In development [GID-TA10871] Expected publication date: 19 March 2025
In development [GID-TA11023] Expected publication date: 30 April 2025